304am永利集团|·主頁(歡迎您)

Be the most trusted biotech company

2024-03-05

Henlius’ Trastuzumab Plots Southeast Asia Expansion, to Enter Thailand and Philippines
2024-03-04

Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development
2024-02-29

Henlius Adalimumab Biosimilar Received sNDA Acceptance Notification from the NMPA
2024-02-19

ASTRUM-004 Featured on the Cover of Cancer Cell
2024-02-01

Henlius Announces Successful Completion of Phase 1 PK Similarity Clinical Study of Denosumab HLX14
2024-01-25

First International Shipment of HANSIZHUANG
2024-01-17

Results from Clinical Trials of Two Henlius’ Novel Products Released at ASCO GI 2024
2024-01-11

Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
2024-01-05

Cancer Cell Published the Results of ASTRUM-004: HANSIZHUANG Combined with Chemotherapy for the First-line Treatment of sqNSCLC

1
...
6
7
8
9
10